Latest News

PBTC and Senhwa sign cooperation agreement to develop CX-4945 for pediatric brain tumor treatment

Jun

12

2018

Senhwa announces the result of phase I data of CX-5461 in the treatment of Hematological malignancies

Dec

12

2017

Senhwa won the National Innovation Award with novelty of CX-5461

Nov

17

2017

Senhwa CX-5461 phase I data of Hematological malignancies was accepted and will be published at the 59th ASH annual meeting

Oct

16

2017

Senhwa CX-5461 in line with the trend of DDR mechanism in anticancer drug development

Sep

19

2017

Notice of US subsidiary changes corporate name

Sep

07

2017

Senhwa filed an application for a patent of combination therapy of CX-4945 and CX-5461 in cancer treatment

Jul

17

2017

Senhwa CX-5461 has the potential to obtain accelerated approval for multiple indications with common biomarker

Jun

17

2017